Jamie Brower

Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas

Peter A. Riedell, Wei‐Ting Hwang, Loretta J. Nastoupil et al. · Transplantation and Cellular Therapy · 2022 · 77 citations · Full text

Medicine, Oncology, Pharmacology +12

Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing

Angela R. Bradbury, Linda Patrick‐Miller, Brian L. Egleston et al. · Genetics in Medicine · 2015 · 68 citations · Full text

Medicine, Cancer Biology, Oncology +4

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Kitsada Wudhikarn, Ana Alarcón Tomás, Jessica Flynn et al. · Blood Advances · 2022 · 41 citations · Full text

Medicine, Hematology, Oncology +16

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Michael Scordo, Jessica Flynn, Mithat Gönen et al. · Blood Advances · 2023 · 35 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

Nausheen Ahmed, William Wesson, Forat Lutfi et al. · Blood Advances · 2024 · 33 citations · Full text

Engineering, Pharmacology, Instrumentation +1